Cancer therapy based on p53

Cancer Journal from Scientific American

Volumn 5, Issue 3, 1999, Pages 139-144

  McCormick, Frank ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Cancer Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

CANCER; CELL PROLIFERATION; GENE MUTATION; HUMAN; ONCOGENE; PRIORITY JOURNAL; RETINOBLASTOMA; REVIEW;

ADENOVIRIDAE; ANIMALS; CLINICAL TRIALS, PHASE I; FORECASTING; GENE THERAPY; HUMANS; MICE; MUTATION; NEOPLASMS; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032977041     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-1677.
2. Tetsu O, McCormick F. Beta-catenin regulates cyclin D1 expression in colon carcinoma cells. Nature; in press
3. Kiyono T, Foster SA, Koop JI et al Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998;396:84-88.
4. Erickson S, Sangfelt O, Heyman M et al. Involvement of the Ink4 proteins p16 and p15 in T-lymphocyte senescence. Oncogene 1998;17:595-602.
5. Brenner AJ, Stampfer MR, Aldaz CM. Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. Oncogene 1998;17:199-205.
6. Chen PL, Riley DJ, Chen Y et al. Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs. Genes Dev 1996;10:2794-2804.
7. Bates S, Phillips AC, Clark PA et al. p14ARF links the tumour suppressors RB and p53. Nature 1998;395:124-125.
8. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev 1998;12:2984-2991.
9. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331.
10. Stott FJ, Bates S, James MC et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998;17:5001-5014.
11. Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979;17:43-52.
12. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979;278:261-263.
13. Dyson, N, Bernards R, Friend SH et al. Large T antigens of many polyomaviruses are able to form complexes with the retinoblastoma protein. J Virol 1990;64:1353-1356.
14. Shenk T. Adenoviridae: the viruses and their replication. Fields BN, Knipe DM, Howley PM, eds. In: Virology. Philadelphia: Lippincott-Raven, 1996:2111-2148.
15. Dobbelstein M, Roth J, Kimberly WT et al. Nuclear export of the E1B 55-kDa and E4 34-kDa adenoviral oncoproteins mediated by a rev-like signal sequence. Embo J 1997;16:4276-4284.
16. Dobner T, Horikoshi N, Rubenwolf S et al. Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumot suppressor. Science 1996;272:1470-1473.
17. Bischoff JR, Kirn DH, Williams A et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-376.
18. Barker DD, Berk AJ. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 1987;156:107-121.
19. Kirn D, Hermiston T, McCormick F. ONYX-015: clinical data are encouraging. Nat Med 1998;4:1341-1342.
20. Heise C, Sampson-Johannes A, Williams A et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997;3:639-645.
21. Howley PM, Munger K, Werness BA et al. Molecular mechanisms of transformation by the human papillomaviruses. Princess Takamatsu Symp 1989;20:199-206.
22. Rothmann T, Hengstermann A, Whitaker NJ et al. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 1998;72:9470-9478.
23. Goodrum FD, Ornelles DA. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol 1998;72:9479-9490.
24. Turnell AS, Grand RJA, Gallimore PH. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status. J Virol 1999;73:2074-2083.
25. Babiss LE, Ginsberg HS, Darnell JE Jr. Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport. Mol Cell Biol 1985;5:2552-2558.
26. Leppard KN, Shenk T. The adenovirus E1B 55 kd protein influences mRNA transport via an intranuclear effect on RNA metabolism. EMBO J 1989;8:2329-2336.
27. Horridge JJ, Leppard KN. RNA-binding activity of the E1B 55-kilodalton protein from human adenovirus type 5. J Virol 1998;72:9374-9379.
28. Gabler S, Schutt H, Groitl P et al. E1B 55-kilodalton-associated protein: a cellular protein with RNA-binding activity implicated in nucleocytoplasmic transport of adenovirus and cellular mRNAs. J Virol 1998;72:7960-7971.
29. Fornerod M, Ohno M, Yoshida M et al. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 1997;90:1051-1060.
30. Fukuda M, Asano S, Nakamura T et al. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 1997;390:308-311.
31. Kirn D. Selectively replicating viruses as therapeutic genes against cancer. In: Lattine EC, Gerson SL, eds. Gene Therapy of Cancer 1999. Burlington, MA: Academic Press, 1999:235-248.